Drug Database
Back to search

Ireland· IE-PA-PA22657/001/001

Dipentum 250mg hard Capsules

A olsalazine product containing olsalazine sodium, registered in Ireland by Atnahs Pharma Netherlands B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC A07EC03

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedDipentum 250mg hard CapsulesATCA07EC03REGISTER NO.IE-PA-PA22657/001/001PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about olsalazine sodiumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Olsalazine is registered in 11 of 19 countries.

Countries holding a registration under ATC A07EC03 (olsalazine), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 5 of them publish a price we can compare per daily dose
Search olsalazine products by name

Olsalazine · ATC A07EC03

11 / 19 countries

  • Canada
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of olsalazine costs, country by country.

Normalised to the WHO defined daily dose (1 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Olsalazine · price per daily dose (1 g)

USD · FX 28 Sept 2026

  • FR France$1.44
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
Olsalazine sodium
Manufacturer
Atnahs Pharma Netherlands B.V.
Country
Ireland (IE)
ATC code
A07EC03
ATC class
Olsalazine
Defined daily dose
1 g, O
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    PA22657/001/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

110 interactions on record for olsalazine.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check olsalazine against other medicinesHow interaction checks work

Olsalazine · interactions on record

110 records

  • 15 severe
  • 93 moderate
  • 2 minor

Most severe, free to view

  • CidofovirJ05AB12severe
  • Humane Immunglobuline, unspezifisch, extravaskulärJ06BA01severe
  • Humane Immunglobuline, unspezifisch, intravaskulärJ06BA02severe
  • SirolimusL01EG04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Olsalazine in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All olsalazine products

Authorised across Europe · EMA

The same active substance is authorised in 9 EEA countries. Names it is sold under:

  • Germany · Dipentum
  • Denmark · Dipentum
  • Finland · Dipentum
  • France · Dipentum
  • United Kingdom (Northern Ireland) · Olsalazine Sodium Atnahs Pharma Uk
  • Iceland · Dipentum
  • Netherlands · Dipentum
  • Norway · Dipentum
  • Sweden · Dipentum

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b3105298-5abc-459f-8de8-335caf9e7e5f
GET /v1/drugs/b3105298-5abc-459f-8de8-335caf9e7e5f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "A07EC",
    "A07EC03"
  ],
  "strength": null,
  "pa_number": "PA22657/001/001",
  "substances": [
    "Olsalazine sodium"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Marketed",
  "authorised_at": "12/07/1995",
  "dispensing_status": "Product subject to prescription which may be renewed (B)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}
API referenceMCP serverPlans

See everything about olsalazine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console